$0.1710
N/A
Last update: Nov 11, 7:07 PM
Kala Bio Inc
KALANASDAQ
Kala Bio fell 99.5% from $37.28 to $0.17, behind the S&P 500's +11.2%. Its worst day was May 7 (−27.8%), and its low came Nov 5 at $0.15.
Nov 11, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-53.50 beat the $-68.00 estimate on $0.00 revenue.
−8.1% · S&P 500 +0.4%
Kala Bio closed at its highest level of the year, 78.4% above where the year started.
Story events cover the past 12 months · Times ET
+37.7%
Kala is building the Palantir for biotech, just as Palantir built a $250+ billion company by helping governments and enterprises make sense of massive data, Kala is doing the same for the biotech and pharmaceutical
+24.2% · S&P 500 −0.1%
EPS of $43.00 beat the $-38.50 estimate on $0.00 revenue.
−3.9% · S&P 500 +0.2%
Kala Bio shares fell 27.8%, while the S&P 500 fell 0.3%.
−27.8%, the year's worst day · S&P 500 −0.3%
EPS of $-0.14 beat the $-0.20 estimate on $0.00 revenue.
−5.2% · S&P 500 −1.2%
Kala Bio shares rose 26.9%, while the S&P 500 rose 1.0%.
+26.9% · S&P 500 +1.0%
EPS of $-21.32 was reported on $0.00 revenue.
−6.7% · S&P 500 −0.8%
Kala Bio shares fell 27.7%, while the S&P 500 fell 1.1%.
−27.7% · S&P 500 −1.1%
Kala Bio closed at its lowest level of the year, 99.6% below where the year started.
−14.3% · S&P 500 −4.4%
Where it ended: a close of $0.17 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 23, 2026.
Nothing in the past 12 months.
All KALA analyst actionsNothing in the past 12 months.
All KALA dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KALA and SPY from Benzinga historical bars. Not investment advice.
